Payment overview · 2025
General Payments
$1,098.19
62 reported records · 15 companies
Healthcare provider profile · identity verified
Bryce Gibson, MD
Allopathic & Osteopathic Physicians|Family Medicine · MADISONVILLE, KY · NPI 1538570569
Verified facts
What the public records show
CMS Open Payments records show Bryce Gibson, MD received $1,098.19 in general payments during 2025 across 62 reported records.
PFIZER INC. accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $225.62 | 20.5% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $197.80 | 18.0% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $156.40 | 14.2% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.55 | 8.2% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $68.60 | 6.2% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $61.56 | 5.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.72 | 4.9% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $46.10 | 4.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.11 | 3.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.22 | 3.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.12 | 3.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.11 | 3.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.45 | 2.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.99 | 1.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.84 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,098.19 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $225.62 | 13 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $192.25 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $160.31 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $91.78 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.60 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $68.60 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $61.56 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.59 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.72 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $46.10 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.65 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $40.11 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.22 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.12 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.96 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.96 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.37 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.90 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.90 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 47 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 43 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 237 | 119 |
| Gabapentin | Gabapentin | 192 | 65 |
| Lisinopril | Lisinopril | 159 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 149 | 74 |
| Losartan Potassium | Losartan Potassium | 142 | 68 |
| Omeprazole | Omeprazole | 138 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 127 | 57 |
| Furosemide | Furosemide | 99 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 59 |
| Clonazepam | Clonazepam | 91 | 23 |
| Ozempic | Semaglutide | 84 | 20 |
| Metformin Hcl | Metformin Hcl | 82 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 81 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 71 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 69 | 34 |
| Temazepam | Temazepam | 68 | 17 |
| Sertraline Hcl | Sertraline Hcl | 66 | 29 |
| Trazodone Hcl | Trazodone Hcl | 65 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 32 |
| Carvedilol | Carvedilol | 60 | 33 |
| Buspirone Hcl | Buspirone Hcl | 56 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 26 |
| Farxiga | Dapagliflozin Propanediol | 53 | 22 |
| Montelukast Sodium | Montelukast Sodium | 52 | 23 |
| Prednisone | Prednisone | 52 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 29 |
| Eliquis | Apixaban | 47 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 23 |
| Spironolactone | Spironolactone | 44 | 21 |
| Jardiance | Empagliflozin | 43 | 17 |
| Allopurinol | Allopurinol | 42 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 12 |
| Lorazepam | Lorazepam | 41 | 11 |
| Meloxicam | Meloxicam | 41 | 27 |
| Simvastatin | Simvastatin | 41 | 24 |
| Famotidine | Famotidine | 40 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 16 |
| Fluconazole | Fluconazole | 36 | 20 |
| Trulicity | Dulaglutide | 36 | 12 |
| Ibuprofen | Ibuprofen | 33 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 15 |
| Tramadol Hcl | Tramadol Hcl | 33 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | 11 |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | 11 |
| Cefdinir | Cefdinir | 22 | 20 |
| Digoxin | Digoxin | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | 13 |
| Nystatin | Nystatin | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 12 |
| Celecoxib | Celecoxib | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,098.19 · 62 records | PFIZER INC. | ACCRUFER, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, INSPIRE, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PROLIA, QULIPTA, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error